You just read:

Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 versus SLT Glaucoma Trial

News provided by

Sight Sciences, Inc.

26 Jul, 2016, 13:04 ET